WINDTREE THERAPEUTICS NEW(WINT)
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- Exchange
- OTC Link
WINDTREE THERAPEUTICS NEW
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | -22.71% | 7 |
| Feb | -22.19% | 7 |
| Mar | -18.43% | 7 |
| Apr | -1.81% | 8 |
| May | -20.31% | 9 |
| Jun | -8.18% | 8 |
| Jul | +30.35% | 7 |
| Aug | -13.35% | 7 |
| Sep | -20.10% | 7 |
| Oct | -10.44% | 7 |
| Nov | -10.69% | 7 |
| Dec | -21.52% | 7 |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Enter a ticker to render the implied volatility surface.
- Beta (1Y vs SPY)
- 1.22
- Correlation (SPY)
- 7.0%
- R²
- 0.00
- Ann. Volatility
- 213.3%
- SPY Volatility
- 12.2%
High volatility - stock moves more than market
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2024-10-09 | Craig Fraser | President and CEO | Buy (P) | +5,431 | $0.91 | $4.9K | EDGAR |
| 2024-07-24 | Craig Fraser | President and CEO | Grant (A) | +4,030 RSU | — | EDGAR | |
| 2024-07-24 | Steven Simonson | SVP, Chief Medical Officer | Grant (A) | +2,687 RSU | — | EDGAR | |
| 2023-09-28 | Craig Fraser | President and CEO | Buy (P) | +2,500 | $1.02 | $2.5K | EDGAR |
| 2023-09-27 | Craig Fraser | President and CEO | Buy (P) | +2,500 | $0.90 | $2.2K | EDGAR |
| 2023-08-29 | Daniel E. Geffken | Director | Award (A) | +2,033 | — | EDGAR | |
| 2023-08-25 | ROBERT A SCOTT | Director | Award (A) | +2,033 | — | EDGAR | |
| 2023-08-25 | Craig Fraser | President and CEO | Award (A) | +45,867 | — | EDGAR | |
| 2023-08-25 | Leslie J. Williams | Director | Award (A) | +2,033 | — | EDGAR | |
| 2023-08-25 | Mark Strobeck | Director | Award (A) | +2,300 | — | EDGAR | |
| 2023-08-25 | Steven Simonson | SVP, Chief Medical Officer | Award (A) | +15,867 | — | EDGAR | |
| 2023-08-25 | Eric Curtis | SVP & COO | Award (A) | +14,667 | — | EDGAR | |
| 2023-04-27 | Craig Fraser | President and CEO | Buy (P) | +1,497 | $1.77 | $2.6K | EDGAR |
| 2023-04-26 | Craig Fraser | President and CEO | Buy (P) | +1,315 | $1.89 | $2.5K | EDGAR |
| 2023-03-02 | Eric Curtis | SVP & COO | Tax (F) | −99 | — | EDGAR |
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Lee's Pharmaceutical Holdings Ltd | 10%+ Owner | 17,370,770 | $250.1K | $47.06M | 3 | 2019-12-10 |
| 2 | LPH II Investments Ltd | 10%+ Owner | 4,008,234 | $57.7K | $10.99M | 2 | 2019-12-10 |
| 3 | James Huang | Director | 3,745,442 | $53.9K | $7.73M | 17 | 2023-02-23 |
| 4 | Center Laboratories, Inc. | 10%+ Owner | 2,423,004 | $34.9K | $2.38M | 1 | 2022-01-10 |
| 5 | John P. Hamill | SVP & CFO | 72,800 | $1.0K | $13.3K | 7 | 2022-07-26 |
| 6 | Steven Simonson | SVP, Chief Medical Officer | 17,446 | $251 | $13.6K | 19 | 2024-07-24 |
| 7 | Eric Curtis | SVP & COO | 15,920 | $229 | $4.6K | 7 | 2023-08-25 |
| 8 | John A Tattory | SVP & CFO | 9,517 | $137 | $3.3K | 10 | 2020-05-27 |
| 9 | BRUCE PEACOCK | Director | 8,886 | $128 | $25.4K | 7 | 2021-02-05 |
| 10 | Craig Fraser | President and CEO | 8,639 | $124 | $95.7K | 46 | 2024-10-09 |
| 11 | John R Leone | Director | 7,473 | $108 | $15.0K | 7 | 2021-02-05 |
| 12 | Mahady M Joseph | Director | 7,455 | $107 | $15.0K | 7 | 2021-02-05 |
| 13 | MARVIN E ROSENTHALE | Director | 7,282 | $105 | $0 | 1 | 2016-08-08 |
| 14 | Mark Strobeck | Director | 2,300 | $33 | $0 | 1 | 2023-08-25 |
| 15 | Daniel E. Geffken | Director | 2,175 | $31 | $15.0K | 6 | 2023-08-29 |
| 16 | ROBERT A SCOTT | Director | 2,133 | $31 | $0 | 3 | 2023-08-25 |
| 17 | Leslie J. Williams | Director | 2,133 | $31 | $0 | 3 | 2023-08-25 |
| 18 | Brian D Schreiber | Director | 2,069 | $30 | $15.0K | 3 | 2021-02-05 |
| 19 | Mary B Esq Templeton | SVP, Gen Counsel & Corp Sec | 1,466 | $21 | $8.0K | 5 | 2020-05-27 |
| 20 | DIANE CARMAN | SVP & General Counsel | 1,227 | $18 | $0 | 3 | 2023-03-02 |
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.